|
1
|
Smaili F, Boudjella A, Dib A, Braikia S,
Zidane H, Reggad R, Bendib A, Abdelouahab A, Bereksi-Reguig F,
Yekrou D, et al: Epidemiology of breast cancer in women based on
diagnosis data from oncologists and senologists in Algeria. Cancer
Treat Res Commun. 25:1002202020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chelmow D, Pearlman MD, Young A, Bozzuto
L, Dayaratna S, Jeudy M, Kremer ME, Scott DM and O'Hara JS:
Executive summary of the early-onset breast cancer evidence review
conference. Obstet Gynecol. 135:1457–1478. 2020. View Article : Google Scholar
|
|
3
|
Kontomanolis EN, Koutras A, Syllaios A,
Schizas D, Mastoraki A, Garmpis N, Diakosavvas M, Angelou K,
Tsatsaris G, Pagkalos A, et al: Role of oncogenes and
tumor-suppressor genes in carcinogenesis: A Review. Anticancer Res.
40:6009–6015. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Falzone L, Grimaldi M, Celentano E,
Augustin LSA and Libra M: Identification of modulated micrornas
associated with breast cancer, diet, and physical activity. Cancers
(Basel). 12:25552020. View Article : Google Scholar
|
|
5
|
Cocco S, Piezzo M, Calabrese A, Cianniello
D, Caputo R, Lauro VD, Fusco G, Gioia GD, Licenziato M and De
Laurentiis M: Biomarkers in Triple-negative breast cancer:
State-of-the-Art and future perspectives. Int J Mol Sci.
21:45792020. View Article : Google Scholar
|
|
6
|
Han Y, Wang J and Xu B: Novel biomarkers
and prediction model for the pathological complete response to
neoadjuvant treatment of triple-negative breast cancer. J Cancer.
12:936–945. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sporikova Z, Koudelakova V, Trojanec R and
Hajduch M: Genetic markers in triple-negative breast cancer. Clin
Breast Cancer. 18:e841–e850. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang N and Pati D: Sororin is a master
regulator of sister chromatid cohesion and separation. Cell Cycle.
11:2073–2083. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jordan PW, Eyster C, Chen J, Pezza RJ and
Rankin S: Sororin is enriched at the central region of synapsed
meiotic chromosomes. Chromosome Res. 25:115–128. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chang IW, Lin VC, He HL, Hsu CT, Li CC, Wu
WJ, Huang CN, Wu TF and Li CF: CDCA5 overexpression is an indicator
of poor prognosis in patients with urothelial carcinomas of the
upper urinary tract and urinary bladder. Am J Transl Res.
7:710–722. 2015.PubMed/NCBI
|
|
11
|
Xu T, Ma M, Dai J, Yu S, Wu X, Tang H, Yu
J, Yan J, Yu H, Chi Z, et al: Gene expression screening identifies
CDCA5 as a potential therapeutic target in acral melanoma. Hum
Pathol. 75:137–145. 2018. View Article : Google Scholar
|
|
12
|
Zhang Z, Shen M and Zhou G: Upregulation
of CDCA5 promotes gastric cancer malignant progression via
influencing cyclin E1. Biochem Biophys Res Commun. 496:482–489.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fu G, Xu Z, Chen X, Pan H, Wang Y and Jin
B: CDCA5 functions as a tumor promoter in bladder cancer by
dysregulating mitochondria-mediated apoptosis, cell cycle
regulation and PI3k/AKT/mTOR pathway activation. J Cancer.
11:2408–2420. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fu Y, Zhou QZ, Zhang XL, Wang ZZ and Wang
P: Identification of hub genes using Co-Expression network analysis
in breast cancer as a tool to predict different stages. Med Sci
Monit. 25:8873–8890. 2019. View Article : Google Scholar
|
|
15
|
Zhang N, Coutinho LE and Pati D: PDS5A and
PDS5B in cohesin function and human disease. Int J Mol Sci.
22:58682021. View Article : Google Scholar
|
|
16
|
Morales C, Ruiz-Torres M, Rodríguez-Acebes
S, Lafarga V, Rodríguez-Corsino M, Megías D, Cisneros DA, Peters
JM, Méndez J and Losada A: PDS5 proteins are required for proper
cohesin dynamics and participate in replication fork protection. J
Biol Chem. 295:146–157. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hagemann C, Weigelin B, Schommer S,
Schulze M, Al-Jomah N, Anacker J, Gerngras S, Kühnel S, Kessler AF,
Polat B, et al: The cohesin-interacting protein, precocious
dissociation of Sisters 5A/sister chromatid cohesion protein 112,
is up-regulated in human astrocytic tumors. Int J Mol Med.
27:39–51. 2011.PubMed/NCBI
|
|
18
|
Zheng MZ, Zheng LM and Zeng YX: SCC-112
gene is involved in tumor progression and promotes the cell
proliferation in G2/M phase. J Cancer Res Clin Oncol. 134:453–462.
2008. View Article : Google Scholar
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data suing real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Phan NN, Wang CY, Li KL, Chen CF, Chiao
CC, Yu HG, Huang PL and Lin YC: Distinct expression of CDCA3,
CDCA5, and CDCA8 leads to shorter relapse free survival in breast
cancer patient. Oncotarget. 9:6977–6992. 2018. View Article : Google Scholar
|
|
21
|
Tian Y, Wu J, Chagas C, Du Y, Lyu H, He Y,
Qi S, Peng Y and Hu J: CDCA5 overexpression is an Indicator of poor
prognosis in patients with hepatocellular carcinoma (HCC). BMC
Cancer. 18:11872018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen H, Chen J, Zhao L, Song W, Xuan Z,
Chen J, Li Z, Song G, Hong L, Song P and Zheng S: CDCA5,
Transcribed by E2F1, promotes oncogenesis by enhancing cell
proliferation and inhibiting apoptosis via the AKT pathway in
hepatocellular carcinoma. J Cancer. 10:1846–1854. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kumar D, Sakabe I, Patel S, Zhang Y, Ahmad
I, Gehan EA, Whiteside TL and Kasid U: SCC-112, a novel cell
cycle-regulated molecule, exhibits reduced expression in human
renal carcinomas. Gene. 328:187–196. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hill VK, Kim JS and Waldman T: Cohesin
mutations in human cancer. Biochim Biophys Acta. 1866:1–11.
2016.
|
|
25
|
Put N, Van Roosbroeck K, Vande Broek I,
Michaux L and Vandenberghe P: PDS5A, a novel translocation partner
of MLL in acute myeloid leukemia. Leuk Res. 36:e87–e89. 2012.
View Article : Google Scholar : PubMed/NCBI
|
